Novo Nordisk Faces Dual Setbacks as Growth Slows and Acquisition Battle Intensifies

Danish pharmaceutical leader Novo Nordisk delivered a double blow to investors this Wednesday, presenting both another reduction in annual targets and an escalating multi-billion dollar contest for U.S. biotech firm Metsera. With the remarkable success of its flagship products Ozempic and Wegovy showing signs of stagnation, the company’s recently appointed chief executive is adopting a bold strategic shift. Market participants are now questioning whether this assertive new direction can successfully reverse the current trend.

Aggressive Acquisition Strategy Amid Market Pressures

In a move highlighting its revised strategic priorities, Novo Nordisk has significantly increased its unsolicited bid to acquire Metsera, now valuing the U.S. biotech specialist at up to $10 billion. This action directly challenges an existing acquisition agreement between Metsera and pharmaceutical titan Pfizer. Adding a compelling twist, Metsera’s board of directors has publicly characterized Novo Nordisk’s revised proposal as “superior,” signaling a potential turning point in the bidding competition. The target company is known for developing next-generation obesity treatments, which could substantially enhance Novo Nordisk’s research pipeline. Pfizer has responded to this competitive maneuver by indicating it will pursue legal avenues.

This acquisition push occurs alongside significant internal restructuring under the leadership of new CEO Maziar Mike Doustdar, who assumed his role in August 2025. The company’s recent takeover of Akero Therapeutics further demonstrates this aggressive mergers and acquisitions approach. Doustdar appears determined to maintain Novo Nordisk’s competitive edge in the fiercely contested weight-loss medication sector through external innovation, particularly as rival Eli Lilly rapidly gains market share with its products Mounjaro and Zepbound.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Quarterly Performance Misses Expectations

The company’s third-quarter 2025 results revealed concerning trends, showing a noticeable deceleration in the growth trajectory of its profitable diabetes and weight-management pharmaceuticals. For the fourth time this year, management has been compelled to downgrade its full-year outlook. Revenue growth projections have been trimmed from the previously anticipated range of 8-14 percent down to 8-11 percent. An even more substantial revision was applied to operating profit expectations, which were sharply reduced from 4-10 percent growth to a modest 4-7 percent.

The market response was swift and severe, with Novo Nordisk’s shares declining immediately at market opening. The disappointing performance compounds an already difficult year for investors, as the stock has lost approximately half its value year-to-date and currently trades significantly below all key moving averages.

Leadership Transition Brings Organizational Overhaul

CEO Maziar Mike Doustdar’s comprehensive corporate restructuring has involved substantial cost, with restructuring charges alone reaching approximately 9 billion Danish kroner in the third quarter. The company’s forthcoming extraordinary general meeting on November 14th, where new board members will be elected, represents a critical juncture for Doustdar’s strategic vision. While his aggressive posture aims to reposition Novo Nordisk for future growth, the substantial restructuring expenses and ambitious acquisition strategy have left investors understandably cautious about the company’s near-term prospects.